Biolase with ticker code (BIOL) now have 4 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The target price ranges between 2 and 1.5 and has a mean target at 1.88. Now with the previous closing price of 1.21 this indicates there is a potential upside of 55.4%. There is a 50 day moving average of 0.82 and the 200 day moving average is 0.44. The market cap for the company is $170m. You can visit the company’s website by visiting: http://www.biolase.com
BIOLASE, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems to perform soft tissue, hygiene, cosmetic procedures, and teeth whitening, as well as to provide temporary pain relief; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology and changed its name to BIOLASE in 2012. BIOLASE was founded in 1984 and is headquartered in Irvine, California.